Difference between revisions of "Tirabrutinib (Velexbru)"
Jump to navigation
Jump to search
m |
m |
||
| Line 3: | Line 3: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | *[[CNS lymphoma]] | ||
*[[Waldenström macroglobulinemia]] | *[[Waldenström macroglobulinemia]] | ||
==History of changes in PMDA indication== | ==History of changes in PMDA indication== | ||
| + | *2020-03-25: Newly indicated for the treatment of relapsed or refractory primary [[CNS lymphoma|central nervous system (CNS) lymphoma]]. | ||
*2020-08-21: new indications for the treatment of [[Waldenström macroglobulinemia|Waldenström's macroglobulinemia]] and lymphoplasmacytic lymphoma. | *2020-08-21: new indications for the treatment of [[Waldenström macroglobulinemia|Waldenström's macroglobulinemia]] and lymphoplasmacytic lymphoma. | ||
| Line 15: | Line 17: | ||
[[Category:BTK inhibitors]] | [[Category:BTK inhibitors]] | ||
| + | [[Category:CNS lymphoma medications]] | ||
[[Category:Waldenström macroglobulinemia medications]] | [[Category:Waldenström macroglobulinemia medications]] | ||
[[Category:PMDA approved drugs]] | [[Category:PMDA approved drugs]] | ||
Revision as of 16:54, 8 June 2023
Mechanism of action
BTK inhibitor
Diseases for which it is used
History of changes in PMDA indication
- 2020-03-25: Newly indicated for the treatment of relapsed or refractory primary central nervous system (CNS) lymphoma.
- 2020-08-21: new indications for the treatment of Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma.
Also known as
- Code name: GS-4059
- Brand name: Velexbru